<p>, /PRNewswire/ -- QuidelOrtho Corporation（纳斯达克代码：QDEL），全球体外诊断领域的领导者，发布了其 <em>Science Bytes</em> 播客的第 54 集，特邀嘉宾为 QuidelOrtho 的研发执行副总裁兼首席技术官 Jonathan Siegrist 博士。Siegrist 博士是分子诊断和生物医学工程领域的公认领导者，推动着创新和下一代诊断解决方案的发展。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2848324/QuidelOrtho_Science_Bytes_Episode_54.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2848324/QuidelOrtho_Science_Bytes_Episode_54.jpg"/></p>
<p>关键见解包括：</p>
<ul>
<li>更快的心脏护理：高灵敏度肌钙蛋白检测加速心脏病患者的诊断和治疗。</li>
<li>非侵入性解决方案：新检测增强了胃肠健康，无需侵入性程序。</li>
<li>快速响应：组合检测帮助临床医生高效管理呼吸系统激增。</li>
<li>下一代诊断：分子平台、信息学和人工智能的进步使得更智能、更个性化的护理成为可能。</li>
<li>大规模创新：研发策略正在塑造诊断，以应对全球医疗挑战。</li>
</ul>
<p>在题为 “2025 年诊断趋势与创新” 的这一集中，Siegrist 博士与主持人 Josh Casey 探讨了重新定义患者护理的变革性技术。从高灵敏度肌钙蛋白检测以加快心脏决策，到改善胃肠健康的非侵入性检测，再到应对呼吸系统激增的快速组合检测，以及分子诊断、信息学和人工智能的进步——这些创新正在简化工作流程，指导及时决策，并改善整个护理过程中的结果。</p>
<p>这一集突显了前沿研究和合作如何推动诊断突破，赋能临床医生并改善全球患者的治疗结果。</p>
<p>QuidelOrtho Science Bytes 播客可在主要流媒体平台上收听，网址为：https://www.quidelortho.com/global/en/resources/podcasts/quidelortho-science-bytes。</p>
<p><strong>前瞻性声明</strong></p>
<p>QuidelOrtho Corporation（“QuidelOrtho”）的这一 Science Bytes 播客（“播客”）包含根据 1995 年《私人证券诉讼改革法》定义的 “前瞻性声明”。这些声明是指本文件中包含的任何非严格历史性的陈述，包括但不限于 QuidelOrtho 的商业和其他战略目标及相关假设，包括研发计划及其他未来计划、目标、策略、期望和意图。在不限制前述内容的情况下，诸如 “可能”、“将”、“可以”、“会”、“应该”、“可能”、“期望”、“预期”、“相信”、“估计”、“计划”、“打算”、“目标”、“项目”、“策略”、“未来”、“继续”、“旨在”、“努力”、“寻求” 或类似词汇、表达或这些术语的否定形式或其他可比术语，旨在识别前瞻性声明。这些声明基于 QuidelOrtho 管理层截至本播客日期的信念和期望，并受到重大已知和未知风险和不确定性的影响。实际结果或结果可能与前瞻性声明中所列或暗示的结果显著不同。以下因素可能导致实际结果或结果与前瞻性声明中所列或暗示的结果不同：未能在预期时间内行使收购 LEX Diagnostics 的选项或完成拟议收购，或根本未能完成，包括与 LEX Diagnostics 获得 FDA 批准和满足其他惯例关闭条件和条款相关的风险和不确定性；未能实现收购的预期收益；以及新产品或增强产品的开发延迟或未能获得批准。其他风险和因素在 QuidelOrtho 截至 2024 年 12 月 29 日的 10-K 表格年度报告及随后提交给证券交易委员会（“委员会”）的报告中进行了讨论，包括在 10-K 表格的第一部分，项目 1A，“风险因素” 下。您不应将前瞻性声明视为未来事件的预测，因为这些声明基于可能不会实现的假设，并且本质上是投机性的。所有前瞻性声明均基于 QuidelOrtho 当前可用的信息，仅在本播客日期时有效。QuidelOrtho 没有义务更新本播客中包含的任何前瞻性信息或时间敏感信息，无论是由于新信息、未来事件、期望变化还是其他原因，除非法律要求。</p>
<p><strong>关于 QuidelOrtho Corporation</strong></p>
<p>QuidelOrtho Corporation（纳斯达克代码：QDEL）在临床化学、免疫测定、免疫输血和分子检测方面拥有专业知识，是全球领先的诊断解决方案提供商，提供快速、准确和可靠的结果，帮助改善患者的治疗结果——从护理现场到实验室，从诊所到医院。基于创新的遗产，QuidelOrtho 与医疗服务提供者合作，推动诊断的发展，将洞察与解决方案相结合，为明智的决策和更好的护理定义更清晰的路径。</p>
<p>投资者联系：</p>
<p>Juliet Cunningham</p>
<p>投资者关系副总裁</p>
<p>IR@QuidelOrtho.com</p>
<p>媒体联系：</p>
<p>D. Nikki Wheeler</p>
<p>企业传播高级总监</p>
<p>Media@QuidelOrtho.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2848325/QuidelOrtho_Jonathan_Siegrist.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2848325/QuidelOrtho_Jonathan_Siegrist.jpg"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2838981/QuidelOrtho_Logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2838981/QuidelOrtho_Logo.jpg"/></p>
<p>来源：QuidelOrtho Corporation</p>

QDEL

<p>QuidelOrtho 公司发布了其科学简报播客的第 54 集，邀请了 Jonathan Siegrist 博士讨论诊断领域的创新。主要话题包括用于心脏护理的高灵敏度肌钙蛋白检测、非侵入性胃肠道检测、应对呼吸道激增的快速组合检测，以及分子诊断、信息学和人工智能的进展。该播客强调了这些创新如何改善患者护理和结果。它还包含了关于 QuidelOrtho 战略目标和潜在风险的前瞻性声明。QuidelOrtho 是全球诊断解决方案的领导者，提升了从现场护理到医院环境的患者结果</p>

<p>, /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, has released Episode 54 of its <em>Science Bytes</em> podcast, featuring Jonathan Siegrist, PhD, Executive Vice President of Research &amp; Development and Chief Technology Officer at QuidelOrtho. Dr. Siegrist is a recognized leader in molecular diagnostics and biomedical engineering, driving innovation and next-generation diagnostic solutions.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- QuidelOrtho Corporation（纳斯达克代码：QDEL），全球体外诊断领域的领导者，发布了其 <em>Science Bytes</em> 播客的第 54 集，特邀嘉宾为 QuidelOrtho 的研发执行副总裁兼首席技术官 Jonathan Siegrist 博士。Siegrist 博士是分子诊断和生物医学工程领域的公认领导者，推动着创新和下一代诊断解决方案的发展。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2848324/QuidelOrtho_Science_Bytes_Episode_54.jpg" alt="" original-src="https://mma.prnewswire.com/media/2848324/QuidelOrtho_Science_Bytes_Episode_54.jpg"/></p>
<p>Key insights include:</p>
<div class="lb-trans"><p>关键见解包括：</p>
</div><ul>
<li>Faster cardiac care: High-sensitivity troponin testing accelerates diagnosis and treatment for cardiac patients.</li>
<li>Non-invasive solutions: New assays enhance gastrointestinal health without invasive procedures.</li>
<li>Rapid response: Combo tests help clinicians manage respiratory surges efficiently.</li>
<li>Next-gen diagnostics: Advances in molecular platforms, informatics and AI enable smarter, more personalized care.</li>
<li>Innovation at scale: R&amp;D strategies are shaping diagnostics to meet global healthcare challenges.</li>
</ul>
<div class="lb-trans"><ul>
<li>更快的心脏护理：高灵敏度肌钙蛋白检测加速心脏病患者的诊断和治疗。</li>
<li>非侵入性解决方案：新检测增强了胃肠健康，无需侵入性程序。</li>
<li>快速响应：组合检测帮助临床医生高效管理呼吸系统激增。</li>
<li>下一代诊断：分子平台、信息学和人工智能的进步使得更智能、更个性化的护理成为可能。</li>
<li>大规模创新：研发策略正在塑造诊断，以应对全球医疗挑战。</li>
</ul>
</div><p>In the episode titled &#34;2025 Diagnostic Trends and Innovations,&#34; Dr. Siegrist joins host Josh Casey to explore the transformative technologies redefining patient care. From high-sensitivity troponin testing for faster cardiac decisions to non-invasive assays improving gastrointestinal health, rapid combo tests for respiratory surges, and advances in molecular diagnostics, informatics and AI – these innovations are streamlining workflows, guiding timely decisions and improving outcomes across the continuum of care.</p>
<div class="lb-trans"><p>在题为 “2025 年诊断趋势与创新” 的这一集中，Siegrist 博士与主持人 Josh Casey 探讨了重新定义患者护理的变革性技术。从高灵敏度肌钙蛋白检测以加快心脏决策，到改善胃肠健康的非侵入性检测，再到应对呼吸系统激增的快速组合检测，以及分子诊断、信息学和人工智能的进步——这些创新正在简化工作流程，指导及时决策，并改善整个护理过程中的结果。</p>
</div><p>This episode highlights how cutting-edge research and collaboration are driving diagnostic breakthroughs that empower clinicians and improve patient outcomes worldwide.</p>
<div class="lb-trans"><p>这一集突显了前沿研究和合作如何推动诊断突破，赋能临床医生并改善全球患者的治疗结果。</p>
</div><p>The QuidelOrtho Science Bytes podcast is available on major streaming platforms and at: https://www.quidelortho.com/global/en/resources/podcasts/quidelortho-science-bytes.</p>
<div class="lb-trans"><p>QuidelOrtho Science Bytes 播客可在主要流媒体平台上收听，网址为：https://www.quidelortho.com/global/en/resources/podcasts/quidelortho-science-bytes。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This Science Bytes Podcast (&#34;Podcast&#34;) of QuidelOrtho Corporation (&#34;QuidelOrtho&#34;) contains &#34;forward-looking statements&#34; within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are any statement contained herein that is not strictly historical, including, but not limited to, QuidelOrtho's commercial and other strategic goals, and related assumptions, including research &amp; development initiatives, and other future plans, objectives, strategies, expectations and intentions. Without limiting the foregoing, the words &#34;may,&#34; &#34;will,&#34; &#34;could,&#34; &#34;would,&#34; &#34;should,&#34; &#34;might,&#34; &#34;expect,&#34; &#34;anticipate,&#34; &#34;believe,&#34; &#34;estimate,&#34; &#34;plan,&#34; &#34;intend,&#34; &#34;goal,&#34; &#34;project,&#34; &#34;strategy,&#34; &#34;future,&#34; &#34;continue,&#34; &#34;aim,&#34; &#34;strive,&#34; &#34;seek&#34; or similar words, expressions or the negative of such terms or other comparable terminology are intended to identify forward-looking statements. Such statements are based on the beliefs and expectations of QuidelOrtho's management as of the date of this Podcast and are subject to significant known and unknown risks and uncertainties. Actual results or outcomes may differ significantly from those set forth or implied in the forward-looking statements. The following factors, among others, could cause actual results or outcomes to differ from those set forth or implied in the forward-looking statements: failure to exercise the option to acquire or complete the proposed acquisition of LEX Diagnostics on the anticipated timeline, or at all, including risks and uncertainties related to LEX Diagnostics' ability to secure FDA clearance and satisfy other customary closing conditions and provisions; inability to realize the anticipated benefits of acquisitions; and delays in the development of or failures or delays in the receipt of approvals for new or enhanced products. Additional risks and factors are discussed in QuidelOrtho's Annual Report on Form 10-K for the fiscal year ended December 29, 2024 and subsequent reports filed with the Securities and Exchange Commission (the &#34;Commission&#34;), including under Part I, Item 1A, &#34;Risk Factors&#34; of the Form 10-K. You should not rely on forward-looking statements as predictions of future events because these statements are based on assumptions that may not come true and are speculative by their nature. All forward-looking statements are based on information currently available to QuidelOrtho and speak only as of the date of this Podcast. QuidelOrtho undertakes no obligation to update any of the forward-looking information or time-sensitive information included in this Podcast, whether as a result of new information, future events, changed expectations or otherwise, except as required by law.</p>
<div class="lb-trans"><p>QuidelOrtho Corporation（“QuidelOrtho”）的这一 Science Bytes 播客（“播客”）包含根据 1995 年《私人证券诉讼改革法》定义的 “前瞻性声明”。这些声明是指本文件中包含的任何非严格历史性的陈述，包括但不限于 QuidelOrtho 的商业和其他战略目标及相关假设，包括研发计划及其他未来计划、目标、策略、期望和意图。在不限制前述内容的情况下，诸如 “可能”、“将”、“可以”、“会”、“应该”、“可能”、“期望”、“预期”、“相信”、“估计”、“计划”、“打算”、“目标”、“项目”、“策略”、“未来”、“继续”、“旨在”、“努力”、“寻求” 或类似词汇、表达或这些术语的否定形式或其他可比术语，旨在识别前瞻性声明。这些声明基于 QuidelOrtho 管理层截至本播客日期的信念和期望，并受到重大已知和未知风险和不确定性的影响。实际结果或结果可能与前瞻性声明中所列或暗示的结果显著不同。以下因素可能导致实际结果或结果与前瞻性声明中所列或暗示的结果不同：未能在预期时间内行使收购 LEX Diagnostics 的选项或完成拟议收购，或根本未能完成，包括与 LEX Diagnostics 获得 FDA 批准和满足其他惯例关闭条件和条款相关的风险和不确定性；未能实现收购的预期收益；以及新产品或增强产品的开发延迟或未能获得批准。其他风险和因素在 QuidelOrtho 截至 2024 年 12 月 29 日的 10-K 表格年度报告及随后提交给证券交易委员会（“委员会”）的报告中进行了讨论，包括在 10-K 表格的第一部分，项目 1A，“风险因素” 下。您不应将前瞻性声明视为未来事件的预测，因为这些声明基于可能不会实现的假设，并且本质上是投机性的。所有前瞻性声明均基于 QuidelOrtho 当前可用的信息，仅在本播客日期时有效。QuidelOrtho 没有义务更新本播客中包含的任何前瞻性信息或时间敏感信息，无论是由于新信息、未来事件、期望变化还是其他原因，除非法律要求。</p>
</div><p><strong>About QuidelOrtho Corporation</strong></p>
<div class="lb-trans"><p><strong>关于 QuidelOrtho Corporation</strong></p>
</div><p>With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, delivering fast, accurate and reliable results that help improve patient outcomes – from the point of care to lab, clinic to hospital. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.</p>
<div class="lb-trans"><p>QuidelOrtho Corporation（纳斯达克代码：QDEL）在临床化学、免疫测定、免疫输血和分子检测方面拥有专业知识，是全球领先的诊断解决方案提供商，提供快速、准确和可靠的结果，帮助改善患者的治疗结果——从护理现场到实验室，从诊所到医院。基于创新的遗产，QuidelOrtho 与医疗服务提供者合作，推动诊断的发展，将洞察与解决方案相结合，为明智的决策和更好的护理定义更清晰的路径。</p>
</div><p>Investor Contact:</p>
<div class="lb-trans"><p>投资者联系：</p>
</div><p>Juliet Cunningham</p>
<div class="lb-trans"><p>Juliet Cunningham</p>
</div><p>Vice President, Investor Relations</p>
<div class="lb-trans"><p>投资者关系副总裁</p>
</div><p>IR@QuidelOrtho.com</p>
<div class="lb-trans"><p>IR@QuidelOrtho.com</p>
</div><p>Media Contact:</p>
<div class="lb-trans"><p>媒体联系：</p>
</div><p>D. Nikki Wheeler</p>
<div class="lb-trans"><p>D. Nikki Wheeler</p>
</div><p>Senior Director, Corporate Communications</p>
<div class="lb-trans"><p>企业传播高级总监</p>
</div><p>Media@QuidelOrtho.com</p>
<div class="lb-trans"><p>Media@QuidelOrtho.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2848325/QuidelOrtho_Jonathan_Siegrist.jpg" alt="" original-src="https://mma.prnewswire.com/media/2848325/QuidelOrtho_Jonathan_Siegrist.jpg"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2838981/QuidelOrtho_Logo.jpg" alt="" original-src="https://mma.prnewswire.com/media/2838981/QuidelOrtho_Logo.jpg"/></p>
<p>SOURCE QuidelOrtho Corporation</p>
<div class="lb-trans"><p>来源：QuidelOrtho Corporation</p>
</div>

创新诊断及未来展望 | QuidelOrtho 股票新闻